Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc AGNPF


Primary Symbol: C.AGN

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Algernon Pharmaceuticals Announces Private Placement

GlobeNewswire March 2, 2021

Algernon Pharmaceuticals (CSE:AGN) to conduct DMT Stroke Program study

Brieanna McCutcheon  March 1, 2021

Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research (UK)

GlobeNewswire March 1, 2021

Algernon Pharmaceuticals Appoints VP Research & Operations and Chief Medical Officer

GlobeNewswire March 1, 2021

Algernon Pharmaceuticals (CSE:AGN) CEO to speak at the Psychedelic Capital Virtual Investment Conference

John Ballem  February 25, 2021

Algernon Pharmaceuticals CEO to Speak at the Psychedelic Capital Virtual Investment Conference

GlobeNewswire February 25, 2021

Algernon Turns to Dalton Pharma to Help with Stroke Program

Stockhouse Editorial February 19, 2021

Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke Program

GlobeNewswire February 19, 2021

Algernon Pharmaceuticals (CSE:AGN) releases update on COVID-19 Phase 2b data

Brieanna McCutcheon  February 17, 2021

Algernon Pharmaceuticals Provides Update on COVID-19 Phase 2b Final Study Data

GlobeNewswire February 17, 2021

BTV News Alert Video: Algernon Pharmaceuticals Inc. - Trial Complete for COVID-19 Treatment

Newsfile February 11, 2021

Algernon Pharmaceuticals (CSE:AGN) considers adding lung scarring as an endpoint for its Phase 2b/3 COVID-19 study protocol

John Ballem  February 10, 2021

Lung Scarring Could be Another Endpoint for Algernon’s COVID-19 Study

Stockhouse Editorial February 10, 2021

Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

GlobeNewswire February 10, 2021

Algernon Pharmaceuticals (CSE:AGN) signs agreement with Charles River Laboratories

Brieanna McCutcheon  February 8, 2021

Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies

GlobeNewswire February 8, 2021

Algernon CEO and CSO to Discuss New DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD

GlobeNewswire February 3, 2021

Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT "The Spirit Molecule"

GlobeNewswire February 1, 2021

Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants

GlobeNewswire January 22, 2021

Algernon Approved to Conduct Phase 3 Ifenprodil Study for COVID-19

Stockhouse Editorial January 20, 2021